Akademik Veri Yönetim Sistemi
56th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, Milan, İtalya, 15 - 18 Mayıs 2024, ss.465-466
Objectives and Study: Impaired gastrointestinal mucosa and immunosuppressant therapies increase the risk of secondary infection in inflammatory bowel disease(IBD). However, evaluation of all pathogens in routine clinical practice may not be possible due to technical and financial reasons. This study aims to demonstrate pathogens in children with IBD using gastrointestinal panel (GP). It is the first study in which this method is evaluated in comparison with clinical data of pediatric patients with IBD.
Methods: Children with newly diagnosed IBD and IBD flare were prospectively included in our study. Demographic data, clinical‐laboratory findings, treatments and their duration, disease activation were evaluated. Stool samples of all patients were analyzed by multiplex real time polymerase chain reaction using QIAstat‐Dx GP. GP results and other findings were compared between the two groups.
Results: A total of 35 IBD patients, 18 of whom were previously diagnosed and in flare, were included in the study. Rotavirus was detected in one patient and Blastocystys hominis in the other by routine stool analysis. No microorganism was detected in stool cultures. GP showed pathogenic microorganisms in 40% of the patients. In the positive cases, the prevalence of IBD flare patients was higher (71.4%). EPEC, Campylobacter spp, EAEC, C.difficile and sapovirus were detected in GP. No significant statistical difference was found between positive and negative GP cases were evaluated in terms of new/previously diagnosis, disease duration, clinical‐laboratory findings, disease activation and immunosuppressive treatments used.
Conclusions: In our study, pathogenic microorganisms that could not be detected by routine clinical tests in IBD patients could be detected by GP. The majority of the patients in whom microorganisms were detected by GP were previously diagnosed IBD patients under immunosuppressives. The use of GP in routine practice may be useful in the management of IBD, especially in the diagnosis of secondary infections.